Você procurou por: randomised study (Inglês - Maltês)

randomised comparative study
studju każwali komparattiv

randomised comparative study:
studju randomised komparattiv:

is randomised, double-blind, multinational study.
to trasfużjonijiet ta 'ċelluli ħomor tad- demm f' pazjenti li kienu qed jirċievu l- kimoterapija ġew assessjati fi studju randomized, double- blind, multi- nazzjonali.

randomised phase 3 study vs. chemotherapy (ca209037)
studju każwali ta’ fażi 3 vs. kemoterapija (ca209037)

study enb-009-10 was an open-label, randomised study.
studju enb-009-10 kien open-label, u studju li fih il-parteċipanti jintgħażlu b’mod każwali.

comfort-ii was an open-label, randomised study in 219 patients.
comfort-ii kien studju open-label, randomizzat fost 219-il pazjent.

another randomised study included 66 patients on tacrolimus versus 67 patients on ciclosporin.
studju ieħor ‘randomised’ kien jinkludi 66 pazjent li ħadu tacrolimus kontra s-67 pazjent li ħadu ciclosporin.

or the purpose of the third multicentre, double-blind, randomised study was the assessment of efficacy
l- iskop tat- tielet studju tat- tip "double- blind randomised", li ġie magħmul f 'aktar minn ċentru wieħed, kienet l- evalwazzjoni ta ’ l- effiċjenza u tas- sigurtà ta' 0. 03% tacrolimus ingwent, li ġie applikat darba li

a phase iii randomised study of caelyx versus doxorubicin in patients with metastatic breast cancer was completed in 509 patients.
studju każwali ta’fażi iii ta’ caelyx versus doxorubicin f'pazjenti b'kanċer tas-sider metastatiku tlesta f'509 pazjent.

study enb-006-09/enb-008-10 was an open-label, non-randomised study.
studju enb-006-09/enb-008-10 kien open-label, u studju li fih il-parteċipanti ma ntgħażlux b’mod każwali.

comparative efficacy data from randomised clinical studies are not yet available.
s’issa għadha mhux disponibbli dejta komparattiva dwar l-effikaċja minn studji kliniċi randomizzati.

bo17929 was a phase ii, non-randomised study in patients with metastatic breast cancer whose tumours had progressed during treatment with trastuzumab.
bo17929 kien studju ta’ fażi ii, mhux randomised f’pazjenti b’kanċer metastatiku tas-sider li t-tumuri tagħhom kienu avanzaw waqt kura b’trastuzumab.

none of the patients treated in the osteosarcoma studies were 65 years or older and in the phase iii randomised study, only patients up to the age of 30 years were included.
Ħadd mill-pazjenti trattati fl-istudji ta’ osteosarkoma kienu ta’ 65 jew aktar u fl-istudju randomised tal-fażi iii, pazjenti sa 30 sena biss kineu inklużi.

a phase iiib, randomised study to compare the efficacy, tolerability and safety of anagrelide hydrochloride versus hydroxyurea in high-risk patients with essential thrombocythaemia.
studju ta 'fażi iiib, li fih il- pazjenti ntgħażlu bl- addoċc sabiex iqabbel l- effikaċja, it - tollerabilità u s- sigurtà ta' anagrelide

study enb-002-08/enb-003-08 was an open-label, non-randomised, non-controlled study.
studju enb-002-08/enb-003-08 kien open-label, u studju li fih il-parteċipanti ma ntgħażlux b’mod każwali, u ma kienx ikkontrollat.

it is likely that these adverse reactions also occurred in the large randomised study, but they were not recorded because only serious and life- threatening adverse reactions were collected in that study.
x’aktarx li r-reazzjonijiet avversi seħħew ukoll fl-istudju kbir randomised, iżda ma kienux innotati peress li reazzjonijiet avversi serji jew ta’ theddid għall-ħajja kienu miġburin f’dak l-istudju.

table 4 summary of key results from four phase iii randomised studies evaluating the benefit of mabthera with different chemotherapy regimens in follicular lymphoma
tabella 4 sommarju ta’ riżultati kruċjali minn erba’ studji randomised ta’ fażi iii li vvalutaw il-benefiċċju ta’ mabthera ma’ korsijiet differenti ta’ kimoterapija f’limfoma follikulari

submission of the final clinical study report for study 3066k1-4438-ww, a randomised study comparing 2 intravenous temsirolimus regimens in patients with relapsed, refractory mantle cell lymphoma.
sottomissjoni tar-rapport finali dwar l-istudju kliniku 3066k1-4438-ww, studju randomizzat li jqabbel 2 reġimens ta' temsirolimus intravenuż f'pazjenti b'limfoma taċ-Ċellula mantle, rikaduta, rifrattorja.

localized candida infections as well as herpes zoster were reported at a higher incidence in the mabthera-containing arm of randomised studies.
infezzjonijiet lokalizzati ta’ candida kif ukoll herpes zoster kienu rrappurtati f’inċidenza ogħla fil-grupp tal-istudji randomised li kien fih mabthera.

montagnani et al used the results from the above three studies to provide an overall analysis of randomised studies comparing folfiri and xeliri treatment regimens in the treatment of mcrc.
montagnani et al użaw ir-riżultati mit-tliet studji ta’ fuq biex jipprovdu analiżi globali tal-istudji randomised li qabblu korsijiet ta’ kura ta’ folfiri u xeliri fil-kura ta’ mcrc.